Advancing Companion Animal Care: Latest Insights into CBD Research and the Superior Full-Spectrum Profile of HEMP DROPS™
As veterinary professionals committed to delivering cutting-edge, evidence-based care, you're no doubt aware of the transformative potential of cannabidiol (CBD) in supporting pet wellness. With pet owners increasingly seeking natural adjuncts to traditional therapies, integrating trusted, Australian-sourced options like HEMP DROPS™ can elevate your practice by enhancing patient outcomes, fostering client loyalty, and driving sustainable revenue through informed recommendations.
Drawing on the most recent peer-reviewed research (2023–2026), this overview highlights CBD's evolving role in companion animal health, while spotlighting the verified full-spectrum composition of HEMP DROPS™ as confirmed by its latest Certificate of Analysis (CoA). By prescribing this premium nutritional supplement off-label, you empower pet owners to address challenges like chronic pain, anxiety, and inflammation, all within a compliant Schedule 4 framework.
Emerging Evidence: Recent CBD Research Revolutionising Veterinary Practice
The past few years have seen a surge in high-quality studies on CBD for pets, underscoring its safety, tolerability, and therapeutic promise. These findings, backed by rigorous methodologies, provide compelling rationale for off-label use in cases where conventional treatments fall short and position forward-thinking vets as trusted advisors in holistic pet care.
A landmark 2025 study from the Dog Aging Project analysed data from over 47,000 dogs surveyed between 2019 and 2023, revealing that CBD supplementation is most prevalent in older pets with chronic conditions, such as dementia (18.2% usage), osteoarthritis (12.5%), and cancer (10%). Notably, long-term CBD users showed reduced aggression intensity over time, suggesting behavioural benefits that could transform management of age-related irritability. This massive dataset highlights CBD's appeal for senior pets, where it may support quality of life without the side effects of pharmaceuticals - a natural and proven solution for a growing number of pet owners concerned with their ageing dog's restlessness, leading to glowing testimonials and repeat visits.
Scientists studied 47,000 dogs on CBD and found a surprising behavior shift | ScienceDaily
What is that dog taking? CBD supplements could make dogs less aggressive over time, study finds
Building on this, a 2024 Cornell University review synthesised over a dozen studies on CBD dosing in dogs, including a 2023 randomised blinded trial where CBD adjunct to antiepileptic drugs reduced seizure frequency in intractable idiopathic epilepsy. Another 2023 double-blinded crossover study in 51 dogs confirmed CBD's efficacy and safety as an add-on for drug-resistant epilepsy, with significant seizure reductions observed. For pain management, a 2023 investigation found CBD effective in alleviating osteoarthritis symptoms in 80% of dogs, aligning with earlier work on its anti-inflammatory properties. Long-term tolerability was affirmed in a 2024 study, where healthy adult dogs showed no adverse effects from prolonged CBD use.
The ABC’s of cannabidiol (CBD) from hemp | Cornell University College of Veterinary Medicine
In Europe, a 2026 French survey of 2,050 pet owners indicated that 29% of dog owners and 13% of cat owners use CBD, primarily for anxiety and pain, with higher adoption among those with personal CBD experience, signalling the fast growing consumer demand that savvy vets can meet through professional guidance. Closer to home, market insights project the US pet CBD sector (mirroring Australian trends) to hit $576.9 million by 2030, driven by 65% of owners using it for stress relief. A 2025 review of peer-reviewed trials further supports CBD for atopic dermatitis, with doses of 0.07–2 mg/kg twice daily reducing pruritus in dogs, thanks to its modulation of the endocannabinoid system (ECS).
Perception and use of cannabidiol (CBD) by French pet owners - ScienceDirect
CBD for pets: navigating quality assurance, safety standards, and marketing strategies - PMC
These studies collectively affirm CBD's role as a safe, versatile tool (reducing seizures, easing joint pain, and calming behavioural issues) empowering veterinary professionals to offer pet owners a natural pathway to better health. By incorporating such evidence into consultations, you can position your clinic as a leader in innovative animal care.
The Verified Full-Spectrum Excellence of HEMP DROPS™: Backed by Independent Analysis
What sets HEMP DROPS™ apart is its true full-spectrum formulation, harnessing the synergistic "entourage effect" where multiple cannabinoids, terpenes, and flavonoids work together for enhanced efficacy, often outperforming isolates by up to fourfold in pain and inflammation models. This is no mere claim; it's verified by CoAs using UPLC/UV methodology.
The analysis confirms a robust cannabinoid profile in this Australian-grown full-spectrum oil matrix:
- Cannabidiol (CBD): 19.85 mg/mL – The dominant non-psychoactive compound, modulating ECS receptors to support pain relief and anxiety reduction.
- Total CBD (CBD + CBD-A * 0.877): 19.95 mg/mL – Incorporating trace Cannabidiol acid (CBD-A) at 0.12 mg/mL for comprehensive bioavailability.
- Cannabidivarin (CBDV): 0.17 mg/mL – Known for anti-convulsant properties, complementing CBD in epilepsy management.
- Cannabichromene (CBC): 0.17 mg/mL – Enhances anti-inflammatory effects.
- Cannabigerol (CBG): 0.13 mg/mL – Supports neuroprotection and gut health.
- Tetrahydrocannabivarin (THCV): 0.12 mg/mL – Aids appetite regulation and anxiety modulation.
- Delta-9-Tetrahydrocannabinol (D9-THC): 0.13 mg/mL – Minimal levels ensure no psychoactive risk, with Total THC at 0.13 mg/mL (<0.1% w/w).
- Other traces below 0.1 mg/mL: Including D9-THC-A, THCVA, CBG-A, CBN, CBL, CBNA, and D8-THC – Contributing to the entourage synergy without exceeding safe thresholds.
This CoA affirms HEMP DROPS™ as a premium full-spectrum product, ideal for off-label prescribing. Unlike isolates, its natural composition maximises ECS activation, delivering superior results for conditions like arthritis or seizures, as evidenced in recent trials. Pet owners will thank you for recommending a traceable, high-potency option that aligns with their values for natural, effective care.
Elevate Your Practice Today with HEMP DROPS™
Armed with this latest research and the unassailable quality of HEMP DROPS™ full-spectrum profile, you're equipped to confidently prescribe this game-changing supplement. Start with a low dose (0.1–0.2 mg/kg CBD twice daily), titrate based on response, and watch as your patients thrive - boosting client satisfaction and your clinic's reputation.
Contact us at info@HempPet.com.au or visit hemppet.au for batch-specific CoAs, compliance tools, and exclusive veterinary resources.